Related Experiment Video
Updated: May 18, 2026

05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Malar bone metastasis revealing a papillary thyroid carcinoma
Ihsen Slim1, Aida Mhiri, Imène Meddeb
1Department of Nuclear Medicine, Salah Azaiez Institut, University El Manar II, 1006 Tunis, Tunisia.
Case Reports in Otolaryngology
|September 7, 2012
Summary
Malar metastasis, a rare occurrence in thyroid cancer, was identified in a patient with the follicular variant of papillary thyroid carcinoma. This case highlights an extremely uncommon presentation of advanced thyroid malignancy.
Area of Science:
- Oncology
- Head and Neck Surgery
- Pathology
Background:
- Papillary thyroid carcinoma (PTC) is the most prevalent differentiated thyroid malignancy.
- Metastases from PTC typically involve the lungs and bones, with rare occurrences in the oral and maxillofacial regions.
- Malar metastasis from PTC is exceptionally rare.
Purpose of the Study:
- To report the first documented case of malar metastasis from a follicular variant of papillary thyroid carcinoma (FVPTC).
- To highlight the unusual presentation of FVPTC with facial bone involvement.
Main Methods:
- Case report of a 67-year-old female patient.
- Clinical presentation of left cheek pain and swelling.
- Histopathological confirmation of follicular variant of papillary thyroid carcinoma.
- Review of medical history including unspecified left lobo-isthmectomy.
Main Results:
- The patient presented with malar metastasis, a highly unusual site for thyroid cancer spread.
- The metastasis was confirmed to be from a follicular variant of papillary thyroid carcinoma.
- This represents the first reported instance of malar metastasis specifically from FVPTC.
Conclusions:
- Malignant tumors, including rare presentations of thyroid carcinoma, should be considered in the differential diagnosis of unexplained facial swelling and pain.
- This case underscores the importance of considering unusual metastatic patterns in oncology.
- Further research into rare metastatic sites of thyroid cancer is warranted.
